KEGG   NETWORK: N00047Help
Entry
N00047                      Network                                

Name
EML4-ALK fusion kinase to PI3K signaling pathway
Definition
EML4-ALK -> PI3K -> PIP3 -> AKT -| BAD
  Expanded
(238v1,238v2) -> (5290,5291,5293) -> C05981 -> (207,208,10000) -| 572
Class
nt06214 PI3K signaling
nt06266 Non-small cell lung cancer
Type
Variant
Pathway
hsa05223  Non-small cell lung cancer
Disease
H00014  Non-small cell lung cancer
Gene
238  ALK; ALK receptor tyrosine kinase
5290  PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
5291  PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta
5293  PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
207  AKT1; AKT serine/threonine kinase 1
208  AKT2; AKT serine/threonine kinase 2
10000  AKT3; AKT serine/threonine kinase 3
572  BAD; BCL2 associated agonist of cell death
Variant
238v1  EML4-ALK fusion
238v2  First generation TKI-resistant ALK1 mutation
Metabolite
C05981  Phosphatidylinositol-3,4,5-trisphosphate
Reference
  Authors
Roskoski R Jr
  Title
Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
  Journal
Pharmacol Res 68:68-94 (2013)
DOI:10.1016/j.phrs.2012.11.007
Reference
  Authors
Janne PA, Gray N, Settleman J
  Title
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors.
  Journal
Nat Rev Drug Discov 8:709-23 (2009)
DOI:10.1038/nrd2871
Reference
  Authors
Raghav KP, Gonzalez-Angulo AM, Blumenschein GR Jr
  Title
Role of HGF/MET axis in resistance of lung cancer to contemporary management.
  Journal
Transl Lung Cancer Res 1:179-93 (2012)
DOI:10.3978/j.issn.2218-6751.2012.09.04
Reference
  Authors
Solomon B, Wilner KD, Shaw AT
  Title
Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
  Journal
Clin Pharmacol Ther 95:15-23 (2014)
DOI:10.1038/clpt.2013.200

DBGET integrated database retrieval system